x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0011866
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB, IP, IHC |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human CA9 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | CA9 |
| UniProt No. | Q16790 |
| Gene ID | 768 |
| Gene Description | Carbonic anhydrases are a family of ancient zinc metalloenzymes found in almost all living organisms. All CA can be divided into 3 distinct classes that evolved independently and have no significant homology in sequence and overall folding. All functional CA catalyze the reversible hydration of CO2 into HCO3- and H+ and contain a zinc atom in the active sites essential for catalysis. There are many isoforms of CA in mammals and they all belong to the α class.CA9 is a member of α class and is a plasma membrane protein with the catalytic domain in the extracellular space. Its expression is restricted to very few normal tissues. CA9 expression is strongly induced by hypoxia and down-regulated by the wildtype von Hippel–Lindau tumor suppressor protein. CA9 expression is increased in many types of tumors, especially solid hypoxic tumors with a poor responsiveness to the conventional radio- and/or chemo-therapies; CA9 is considered to be a tumor hypoxia marker and a promising target for cancer therapeutic intervention. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
